Other Medical products:

  • EN14683:2019 type II medical face masks
  • 1 ml syringes for COVID-19 Vaccine

GaDia is developing rapid tests for hospital and healthcare centers in the field of infectious diseases

Infections in hospital can quickly be life-threatening. Actual tests are mostly based on the microbial analysis and are time-consuming. With the solution developed by GaDia, physicians can rapidly select the right treatment and save time.

Because time matters !


       Fungal Infections

Globally, over 300 million of people suffer from serious fungal infections every year with 1.6 million of deaths. Many deaths caused by fungal infections are avoidable with a rapid diagnostic and the right treatment.

Our first rapid test is intended to be used as first line screening test in hospital for patients with suspected Candida sp.  fungal infections.

Our patented test differentiates Candida fungal infections from other causes of infection and gives a result in 15 minutes to start the right treatment.

Characteristics of the test

CandiDia is the first rapid immunochromatographic test for the early diagnostic of patients affected by invasive candidiasis and candidemia.

Human Fluid Blood, serum or plasma
Bronchoalveolar lavage (BAL)
Test principle IgG against a patented combination of fungal biomarkers
Diagnostic performances
(consult IFU for more information)
Sensitivity: 95% (IC95: 73-100%)
Specificity: 83% (IC95: 61-94%)
Storage 5-25°C
Availability

2021

CandiDia_Flyer_v1.0

Buy Now

Our rapid test detects the Galactomannan antigen from Aspergillus sp. in serum or Bronchoalveolar lavage (BAL) in only 15 minutes. More than 300’000 people are affected by Invasive Aspergilosis each year with high mortality rate without a rapid diagnostic and treatment.

Characteristics of the test
Human Fluid Serum or plasma
Bronchoalveolar lavage (BAL)
Test principle Detection of Galactomannan antigen
Diagnostic performances
(on BAL samples, consult IFU for more information)
Sensitivity: 90.3% (IC95: 82.9-94.8%)
Specificity: 92.5% (IC95: 87.8-95.6%)
Storage 5-25°C
Availability

2021, CE-IVD

Flyer Aspergillus Ag

Buy Now

 

Our rapid immunechromatographic assay detects of the capsular polysaccharide antigens of Cryptococcus sp. complex (Cryptococcus neoformans and Cryptococcus gattii) in serum, plasma, whole blood and cerebral spinal fluid (CSF)

Characteristics of the test
Human Fluid Whole blood, Serum or plasma
Cerebral spinal fluid (CSF)
Test principle Detection of Cryptococcus sp. capsular antigen
Diagnostic performances
(on CSF samples, consult IFU for more information)
Sensitivity: 99.9% (IC95: 96.6-100%)
Specificity: 99.1% (IC95: 97.1-99.8%)
Storage 5-25°C
Availability

2021, CE-IVD

Flyer Cryptococcal Ag

Buy Now


    Viral Infections

Viral Infections are among the leading causes of deaths due in adults living in low and middle income countries. Treatment for these  diseases exists, but their effectiveness face numerous challenges including timely diagnosis.

 

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a new strain of coronavirus that has not been previously identified in human. Detection of SARS-CoV-2 IgM and IgG antibodies in human blood can be used as an auxiliary screening tool of COVID-19 infected patients.

PRINCIPLE

The test detects the IgM and IgG specific to nucleocapsid protein (N protein) and spike protein (S protein). 

The test was evaluated at University Hospital of Geneva (HUG) and Lausanne (CHUV) in Switzerland.

ORDER

MORE INFORMATION

Simtomax CoronaCheck_flyer_v7.0

Diagnostic performances

Clinical study at University Hospital Geneva (HUG)

Clinical study at University of Applied Sciences (HES-SO)

COVID-19 Rapid test development

 

Rapid diagnostic test for the detection of Nucleocapsid antigen in Nasopharyngeal swab of COVID-19 suspected patients. The test has been validated for the rapid and easy detection of SARS-CoV-2 antigen in saliva.

Made in Switzerland

Characteristics of the test
Human Fluid Nasopharyngeal Swabs, Nasal swabs and Saliva
Test principle Detection of Nucleocapsid antigen

Diagnostic performances
(consult IFU for more information)

Ref. Ducrest et al. 2021, medRxiv
Compos et al. 2020, medRxiv

Sensitivity: 90.0% (IC95: 81.2-100%)

Sensitivity (CT<30): 100%
Specificity: 97.5% (IC95: 91.9-100%)

Storage 5-30°C
Availability

2021

ORDER